Inbrx 101 Graphic

The Candidate

Our recombinant human AAT-Fc fusion protein.

INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein with the potential to:

  • Extend the dosing range from weekly to every three weeks, while maintaining patients in the normal range of AAT exposure.
  • Overcome challenges of maintaining the function of recombinant AAT, while manufacturing at commercial scale.
  • Is engineered to maximize the functional activity of AAT, particularly in the lungs.
  • Complements RNAi approaches, but addresses all AATD patients.

INBRX-101 vs. Current Therapy

Predicted mean serum AAT levels:

120 mg/kg of INBRX-101 Every 3 Weeks
Inbrx 101 Chart

The current state and standard of care for people with AATD is suboptimal. Receiving plasma-derived AAT with weekly infusions doesn’t maintain normal serum AAT levels. AAT has proven difficult to develop recombinantly, often displaying loss of activity and experiencing accelerated degradation.

We believe our novel approach has the potential to overcome these challenges. Fusion of AAT to the Fc region allows for production using a standard antibody expression system, which, when combined with our proprietary AAT-function preserving purification process, generates substantial and potentially scalable yields of active recombinant AAT protein.

We believe that this extended exposure supports the potential for dosing every three weeks while maintaining patients in the normal range of AAT exposure, which in turn would reduce the frequency of annual infusions, eliminate lung decline from Alpha-1 Disease, and could significantly improve patient quality of life.

Inhibrx Block 04

INBRX-101 Clinical Trial

The Phase 1 dose-escalating trial for INBRX-101 is evaluating the effects of INBRX-101 in patients with Alpha-1 Antitrypsin Deficiency (AATD) who are either treatment naive or previously treated with plasma-derived therapeutics.

clinicaltrials.gov